Literature DB >> 1688406

Cross-reactivity between the EBNA-1 p107 peptide, collagen, and keratin: implications for the pathogenesis of rheumatoid arthritis.

P Birkenfeld1, N Haratz, G Klein, D Sulitzeanu.   

Abstract

An unusually heavy load of Epstein-Barr virus (EBV) infection and autoimmunity to collagen are believed to be contributing factors to the pathogenesis of rheumatoid arthritis (RA). The present report presents data showing that p107, the major epitope of the EBV-encoded EBNA-1 antigen, cross-reacts with denatured collagen (DC) and keratin (K), suggesting a new likely link among RA, EBV-1, and these autoantigens. A radioimmunoassay using antigen-coated microtiter plates was used to demonstrate antibodies in sera of patients with RA and sera of healthy donors against p107, DC, and K. Specificity of the antibodies was ascertained by inhibition tests with the homologous antigens. Cross-reactivity among anti-p107, anti-DC, and anti-K antibodies was assayed by the ability of a given antigen to block the binding of nonpurified or affinity-purified antibodies to plates coated with another antigen. Most of the sera contained antibodies to all three antigens, but only anti-DC antibodies were present in higher titers in RA sera. Preincubation of sera with p107 appreciably reduced their binding to plates coated with DC or K. On the other hand, preincubation with DC (in solution or bound to Sepharose) did not result in consistent reduction of anti-p107 titers. Tests with affinity-purified antibodies revealed the existence of two antibodies populations, one of which reacted preferentially with p107, the other with DC. The cross-reactivity of the anti-p107 antibodies with DC and K suggests that such antibodies, produced by RA patients following persistent stimulation with EBV, might react in vivo with collagen (and keratin) exposed in previously damaged areas and thus reinforce the disease process.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1688406     DOI: 10.1016/0090-1229(90)90002-8

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  14 in total

1.  Epstein-Barr virus serologic abnormalities and risk of rheumatoid arthritis among women.

Authors:  Barbara L Goldstein; Lori B Chibnik; Elizabeth W Karlson; Karen H Costenbader
Journal:  Autoimmunity       Date:  2011-10-20       Impact factor: 2.815

2.  Epstein-Barr virus-induced autoimmune responses. I. Immunoglobulin M autoantibodies to proteins mimicking and not mimicking Epstein-Barr virus nuclear antigen-1.

Authors:  J H Vaughan; J R Valbracht; M D Nguyen; H H Handley; R S Smith; K Patrick; G H Rhodes
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

3.  Cross reaction of antibodies to a glycine/alanine repeat sequence of Epstein-Barr virus nuclear antigen-1 with collagen, cytokeratin, and actin.

Authors:  C Baboonian; P J Venables; D G Williams; R O Williams; R N Maini
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

4.  Delivery of siRNA and other macromolecules into skin and cells using a peptide enhancer.

Authors:  Tracy Hsu; Samir Mitragotri
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-08       Impact factor: 11.205

Review 5.  The Epstein-Barr virus in autoimmunity.

Authors:  J H Vaughan
Journal:  Springer Semin Immunopathol       Date:  1995

6.  Revisiting IgG Antibody Reactivity to Epstein-Barr Virus in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Its Potential Application to Disease Diagnosis.

Authors:  Nuno Sepúlveda; João Malato; Franziska Sotzny; Anna D Grabowska; André Fonseca; Clara Cordeiro; Luís Graça; Przemyslaw Biecek; Uta Behrends; Josef Mautner; Francisco Westermeier; Eliana M Lacerda; Carmen Scheibenbogen
Journal:  Front Med (Lausanne)       Date:  2022-06-24

Review 7.  Epstein-Barr virus, infectious mononucleosis, and posttransplant lymphoproliferative disorders.

Authors:  M A Nalesnik; T E Starzl
Journal:  Transplant Sci       Date:  1994-09

8.  Antibodies specific for Epstein-Barr virus nuclear antigen-1 cross-react with human heterogeneous nuclear ribonucleoprotein L.

Authors:  J William Lindsey; Samantha L deGannes; Kimberly A Pate; Xiurong Zhao
Journal:  Mol Immunol       Date:  2015-11-28       Impact factor: 4.407

9.  Increased IgA antibodies to cytokeratins in the spondyloarthropathies.

Authors:  A A Borg; N B Nixon; P T Dawes; D L Mattey
Journal:  Ann Rheum Dis       Date:  1994-06       Impact factor: 19.103

10.  Very long charge runs in systemic lupus erythematosus-associated autoantigens.

Authors:  V Brendel; J Dohlman; B E Blaisdell; S Karlin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.